Compare FANG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | EW |
|---|---|---|
| Founded | 2007 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8B | 48.9B |
| IPO Year | 2012 | 1999 |
| Metric | FANG | EW |
|---|---|---|
| Price | $185.23 | $85.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 29 |
| Target Price | ★ $234.52 | $100.96 |
| AVG Volume (30 Days) | 2.3M | ★ 2.8M |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.72 | 1.07 |
| Revenue | ★ $15,026,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $31.57 | $11.40 |
| Revenue Next Year | N/A | $9.90 |
| P/E Ratio | ★ $27.49 | $80.95 |
| Revenue Growth | ★ 35.79 | 11.55 |
| 52 Week Low | $137.03 | $72.30 |
| 52 Week High | $216.90 | $96.29 |
| Indicator | FANG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 45.23 |
| Support Level | $169.26 | $83.49 |
| Resistance Level | $186.66 | $89.41 |
| Average True Range (ATR) | 4.45 | 1.81 |
| MACD | -1.31 | -0.02 |
| Stochastic Oscillator | 8.50 | 41.43 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.